Literature DB >> 17357888

[Adalimumab therapy for Vogt-Koyanagi-Harada syndrome].

M Díaz Llopis, L Amselem, F J Romero, S García-Delpech, M L Hernández.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17357888     DOI： 10.4321/s0365-66912007000300003

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN： 0365-6691


× No keyword cloud information.
  3 in total

1.  Rituximab in refractory Vogt-Koyanagi-Harada disease.

Authors:  Rosa Dolz-Marco; Roberto Gallego-Pinazo; Manuel Díaz-Llopis
Journal:  J Ophthalmic Inflamm Infect       Date:  2011-07-09

Review 2.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

3.  Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy.

Authors:  Shizhao Yang; Tianyu Tao; Zhaohao Huang; Xiuxing Liu; He Li; Lihui Xie; Feng Wen; Wei Chi; Wenru Su
Journal:  Front Med (Lausanne)       Date:  2022-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.